These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28009271)

  • 21. Frontotemporal dementia, Parkinsonism and lower motor neuron involvement in a patient with C9ORF72 expansion.
    Luigetti M; Quaranta D; Conte A; Piccininni C; Lattante S; Romano A; Silvestri G; Zollino M; Sabatelli M
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Jan; 14(1):66-9. PubMed ID: 22708871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C9ORF72-ALS/FTD: Transgenic Mice Make a Come-BAC.
    Hayes LR; Rothstein JD
    Neuron; 2016 May; 90(3):427-31. PubMed ID: 27151634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia.
    Gagliardi D; Costamagna G; Taiana M; Andreoli L; Biella F; Bersani M; Bresolin N; Comi GP; Corti S
    Ageing Res Rev; 2020 Dec; 64():101172. PubMed ID: 32971256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts.
    Kramer NJ; Carlomagno Y; Zhang YJ; Almeida S; Cook CN; Gendron TF; Prudencio M; Van Blitterswijk M; Belzil V; Couthouis J; Paul JW; Goodman LD; Daughrity L; Chew J; Garrett A; Pregent L; Jansen-West K; Tabassian LJ; Rademakers R; Boylan K; Graff-Radford NR; Josephs KA; Parisi JE; Knopman DS; Petersen RC; Boeve BF; Deng N; Feng Y; Cheng TH; Dickson DW; Cohen SN; Bonini NM; Link CD; Gao FB; Petrucelli L; Gitler AD
    Science; 2016 Aug; 353(6300):708-12. PubMed ID: 27516603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C9orf72 repeat expansions that cause frontotemporal dementia are detectable among patients with psychosis.
    Watson A; Pribadi M; Chowdari K; Clifton S; Joel Wood ; Miller BL; Coppola G; Nimgaonkar V
    Psychiatry Res; 2016 Jan; 235():200-2. PubMed ID: 26723138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.
    Riboldi G; Zanetta C; Ranieri M; Nizzardo M; Simone C; Magri F; Bresolin N; Comi GP; Corti S
    Mol Neurobiol; 2014 Dec; 50(3):721-32. PubMed ID: 24809691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease.
    Lindquist SG; Duno M; Batbayli M; Puschmann A; Braendgaard H; Mardosiene S; Svenstrup K; Pinborg LH; Vestergaard K; Hjermind LE; Stokholm J; Andersen BB; Johannsen P; Nielsen JE
    Clin Genet; 2013 Mar; 83(3):279-83. PubMed ID: 22650353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural insight into C9orf72 hexanucleotide repeat expansions: Towards new therapeutic targets in FTD-ALS.
    Kumar V; Kashav T; Islam A; Ahmad F; Hassan MI
    Neurochem Int; 2016 Nov; 100():11-20. PubMed ID: 27539655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALS-FTD complex disorder due to C9ORF72 gene mutation: description of first Polish family.
    Siuda J; Lewicka T; Bujak M; Opala G; Golenia A; Slowik A; van Blitterswijk M; Baker M; Ertekin-Taner N; Wszolek ZK; Rademakers R
    Eur Neurol; 2014; 72(1-2):64-71. PubMed ID: 24861139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD.
    Tang X; Toro A; T G S; Gao J; Chalk J; Oskarsson B; Zhang K
    Mol Neurodegener; 2020 Jun; 15(1):34. PubMed ID: 32513219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No common founder for C9orf72 expansion mutation in Sweden.
    Chiang HH; Forsell C; Lindström AK; Lilius L; Thonberg H; Nennesmo I; Graff C
    J Hum Genet; 2017 Feb; 62(2):321-324. PubMed ID: 27557666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.
    Mis MSC; Brajkovic S; Tafuri F; Bresolin N; Comi GP; Corti S
    Mol Neurobiol; 2017 Aug; 54(6):4466-4476. PubMed ID: 27349438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FTD/ALS families are no longer orphaned: the C9ORF72 story.
    van Swieten JC; Grossman M
    Neurology; 2012 Sep; 79(10):962-4. PubMed ID: 22875094
    [No Abstract]   [Full Text] [Related]  

  • 34. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD.
    O'Rourke JG; Bogdanik L; Muhammad AKMG; Gendron TF; Kim KJ; Austin A; Cady J; Liu EY; Zarrow J; Grant S; Ho R; Bell S; Carmona S; Simpkinson M; Lall D; Wu K; Daughrity L; Dickson DW; Harms MB; Petrucelli L; Lee EB; Lutz CM; Baloh RH
    Neuron; 2015 Dec; 88(5):892-901. PubMed ID: 26637796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan.
    Tsai CP; Soong BW; Tu PH; Lin KP; Fuh JL; Tsai PC; Lu YC; Lee IH; Lee YC
    Neurobiol Aging; 2012 Sep; 33(9):2232.e11-2232.e18. PubMed ID: 22673113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD.
    Hukema RK; Riemslagh FW; Melhem S; van der Linde HC; Severijnen LA; Edbauer D; Maas A; Charlet-Berguerand N; Willemsen R; van Swieten JC
    Acta Neuropathol Commun; 2014 Dec; 2():166. PubMed ID: 25523491
    [No Abstract]   [Full Text] [Related]  

  • 37. C9orf72; abnormal RNA expression is the key.
    Heutink P; Jansen IE; Lynes EM
    Exp Neurol; 2014 Dec; 262 Pt B():102-10. PubMed ID: 24873727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain ¹⁸F-FDG and ¹¹C-PiB PET findings in two siblings with FTD/ALS associated with the C9ORF72 repeat expansion.
    Martikainen MH; Gardberg M; Jansson L; Röyttä M; Rinne JO; Kaasinen V
    Neurocase; 2014 Apr; 20(2):150-7. PubMed ID: 23216213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases.
    Hübers A; Marroquin N; Schmoll B; Vielhaber S; Just M; Mayer B; Högel J; Dorst J; Mertens T; Just W; Aulitzky A; Wais V; Ludolph AC; Kubisch C; Weishaupt JH; Volk AE
    Neurobiol Aging; 2014 May; 35(5):1214.e1-6. PubMed ID: 24378086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS.
    Jovičić A; Mertens J; Boeynaems S; Bogaert E; Chai N; Yamada SB; Paul JW; Sun S; Herdy JR; Bieri G; Kramer NJ; Gage FH; Van Den Bosch L; Robberecht W; Gitler AD
    Nat Neurosci; 2015 Sep; 18(9):1226-9. PubMed ID: 26308983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.